MY142283A - Diagnosis and treatment of cancers and other conditions - Google Patents

Diagnosis and treatment of cancers and other conditions

Info

Publication number
MY142283A
MY142283A MYPI20023310A MYPI20023310A MY142283A MY 142283 A MY142283 A MY 142283A MY PI20023310 A MYPI20023310 A MY PI20023310A MY PI20023310 A MYPI20023310 A MY PI20023310A MY 142283 A MY142283 A MY 142283A
Authority
MY
Malaysia
Prior art keywords
probe
receptors
functional
treatment
antibody
Prior art date
Application number
MYPI20023310A
Other languages
English (en)
Inventor
Angus Gidley-Baird
Julian Alexander Barden
Original Assignee
Biosceptre Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR7431A external-priority patent/AUPR743101A0/en
Priority claimed from AUPR7430A external-priority patent/AUPR743001A0/en
Priority claimed from PCT/AU2002/000061 external-priority patent/WO2002057306A1/en
Application filed by Biosceptre Int Ltd filed Critical Biosceptre Int Ltd
Publication of MY142283A publication Critical patent/MY142283A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MYPI20023310A 2001-09-03 2002-09-04 Diagnosis and treatment of cancers and other conditions MY142283A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPR7431A AUPR743101A0 (en) 2001-09-03 2001-09-03 A cancer therapeutic
AUPR7430A AUPR743001A0 (en) 2001-09-03 2001-09-03 Diagnosis and treatment of irritable bowel syndrome
PCT/AU2002/000061 WO2002057306A1 (en) 2001-01-17 2002-01-17 Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions

Publications (1)

Publication Number Publication Date
MY142283A true MY142283A (en) 2010-11-15

Family

ID=41706691

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20023310A MY142283A (en) 2001-09-03 2002-09-04 Diagnosis and treatment of cancers and other conditions

Country Status (9)

Country Link
JP (1) JP4467973B2 (zh)
CN (2) CN101445555B (zh)
AU (1) AU2002322192B2 (zh)
CA (1) CA2459348C (zh)
MY (1) MY142283A (zh)
NZ (2) NZ565994A (zh)
TW (1) TWI329648B (zh)
WO (1) WO2003020762A1 (zh)
ZA (1) ZA200402630B (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE548383T1 (de) 2001-01-17 2012-03-15 Biosceptre Int Ltd Diagnose und behandlung von karzinomen und anderen leiden
EP1570232B1 (en) * 2002-12-05 2016-11-02 KLA-Tencor Technologies Corporation Apparatus and methods for detecting overlay errors using scatterometry
EP1615991A4 (en) 2003-04-03 2007-12-19 Bristol Myers Squibb Co POLYNUCLEOTIDE ENCODING A NEW HUMAN P2X7 SPLICE VARIANT CALLED HBMYP2X7V
US8124730B1 (en) 2004-04-02 2012-02-28 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
US7767789B2 (en) * 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
WO2008043146A1 (en) * 2006-10-10 2008-04-17 Biosceptre International Limited Antibodies against non functional p2x7 receptor
JP2010505426A (ja) * 2006-10-10 2010-02-25 バイオスセプター インターナショナル リミテッド 非機能性ｐ２ｘ７受容体に対する抗体を産生するハイブリドーマ
ATE542139T1 (de) * 2007-09-14 2012-02-15 Biosceptre Int Ltd Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
AU2008299593B2 (en) 2007-09-14 2013-04-18 Biosceptre International Limited Novel P2X7 epitopes
AU2013238152B2 (en) * 2007-09-14 2015-09-24 Biosceptre International Limited Purinergic (P2X) receptors in extra-cellular body fluid
AU2009266430B2 (en) * 2008-07-04 2014-08-14 Biosceptre International Limited Anti- P2X7 peptides and epitopes
CN101469352B (zh) * 2008-08-29 2011-12-21 苏州福英基因科技有限公司 一种早期子宫癌原位杂交检测试剂盒
ES2704711T3 (es) * 2009-08-20 2019-03-19 Biosceptre Aust Pty Ltd Anticuerpos anti-receptor P2X7 y fragmentos de los mismos
WO2011075789A1 (en) 2009-12-24 2011-06-30 Biosceptre International Limited Antibodies to non-functional oligomeric p2x7 receptors
WO2012031333A1 (en) 2010-09-10 2012-03-15 Biosceptre International Limited Companion animal treatments
EP2726095B1 (en) * 2011-07-01 2018-06-06 Biosceptre (Aust) Pty Ltd Combination therapy
EP2990800A1 (en) * 2014-08-29 2016-03-02 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Neprilysin as heartfailure (HF) prognostic marker
AU2016318230B2 (en) 2015-09-11 2020-05-21 Biosceptre (Aust) Pty Ltd Chimeric antigen receptors and uses thereof
CN109862883A (zh) * 2016-10-21 2019-06-07 生物权威（英国）有限公司 细胞毒性颗粒
CN110054691B (zh) * 2019-05-09 2021-09-07 潍坊医学院 一种抗人p2rx7单克隆抗体的杂交瘤细胞系

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133434A (en) * 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
ATE548383T1 (de) * 2001-01-17 2012-03-15 Biosceptre Int Ltd Diagnose und behandlung von karzinomen und anderen leiden

Also Published As

Publication number Publication date
CA2459348C (en) 2013-06-18
CA2459348A1 (en) 2003-03-13
TWI329648B (en) 2010-09-01
JP4467973B2 (ja) 2010-05-26
CN101445555A (zh) 2009-06-03
WO2003020762A1 (en) 2003-03-13
CN100497386C (zh) 2009-06-10
CN101445555B (zh) 2013-07-03
NZ549019A (en) 2008-05-30
JP2005513416A (ja) 2005-05-12
CN1625565A (zh) 2005-06-08
NZ565994A (en) 2010-02-26
ZA200402630B (en) 2005-06-29
AU2002322192B2 (en) 2008-05-01

Similar Documents

Publication Publication Date Title
MY158262A (en) Diagnosis and treatments of cancers and other conditions
MY142283A (en) Diagnosis and treatment of cancers and other conditions
KR100711046B1 (ko) 대장암에 대한 마커로서의 니코틴아미드ｎ―메틸트랜스퍼라아제의 용도
ATE461449T1 (de) Verfahren zum nachweis von medizinisch relevanten zuständen in gelösten lbc-proben
UA90082C2 (ru) Выделенное моноклональное антитело человека, которое специфически связывается с cd25 человека и ингибирует связывание il-2 с cd25
NO20082559L (no) Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer
MXPA03007037A (es) Ligandos del antigeno de membrana especifico de prostata (amep) y usos relacionados del mismo.
HUP0202532A2 (hu) Ko-stimulátor szignál-transzdukciós molekula (AILIM) elleni humán monoklonális antitest és gyógyászati alkalmazása
ZA200508390B (en) Compositions and methods for the therapy of inflammatory bowel disease
EP2021794B8 (en) Use of protein s100a 12 as a marker for colorectal cancer
HUP0303888A2 (hu) FKBP-nukleinsavak és -polipeptidek prosztatarák diagnosztizálására és gyógykezelésére alkalmas expressziós analízise
ATE540979T1 (de) Leptinantagonist und verfahren zur quantitativen messung von leptin
WO2004022006A3 (en) Methods of diagnosing cervical cancer
CY1106688T1 (el) Αποτιμηση κοβαλαμινης
WO2008060376A3 (en) Algorithims for multivariant models to combine a panel of biomarkers for assessing the risk of developing ovarian cancer
DE602005013430D1 (de) Verwendung von asc als marker für kolorektalkarzinome
TR200402517T1 (tr) HBV ilaç direnci tespit metotları
DE602004017317D1 (de) Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome
NO20022441L (no) Fremgangsmåter for å behandle Lupus basert på antistoffaffinitet og screeningsmetoder, og preparater foranvendelse av disse
WO2003104761A3 (en) MEASUREMENT OF MELANOCORTINE PEPTIDES AND USES THEREOF
BR0308117A (pt) Dìmeros de avidina eficazes em aumentar a concentração de biotina radioativa em radioimunoterapia pré-direcionada
DE602004001994D1 (de) Verwendung des proteins masp als marker für kolorektale karzinome
EP0563244A4 (en) Human phospholipase activating protein and methods for diagnosis of rheumatoid arthritis
DE60127935D1 (de) Verfahren zur diagnose der effektivität der xenotypischen antikörpertherapie
BRPI0415562A (pt) reagente para avaliação diagnóstica e/ou prognóstica de carcinoma, métodos para determinação de p-lap que é um fator prognóstico em carcinoma, e para avaliação prognóstica de carcinoma, e, kit de imunoensaio para determinação da quantidade de p-lap presente em tecidos de carcinoma